Clinical Target definition

Clinical Target means a Pre-Clinical Target for which Licensee has exercised the Clinical Option (including payment of the corresponding fee(s) set forth in Section 4.4) to designate such Pre-Clinical Target as a Clinical Target. Clinical Targets are set forth in Exhibit C attached hereto.
View Source

Examples of Clinical Target in a sentence

  • For faculty participating in the FMP, the Clinical Target shall be the 55th percentile of the most recent UHC number for each specialty.

  • Affini-T shall notify Metagenomi within [***] after the first achievement of each of the following Development milestone events with respect to each Affini-T Clinical Target once for each Field.

  • On a Affini-T Clinical Target-by-Affini-T Clinical Target basis, Affini-T shall notify and pay to Metagenomi within [***] after the first achievement of each of the following Commercial sales milestone events as determined by aggregating Net Sales of all Licensed Products directed to a given Affini-T Clinical Target (i.e., all Exclusively Licensed Products and Non-Exclusively Licensed Products directed to a given Affini-T Clinical Target).

  • Affini-T may, at its sole discretion, exercise one or both of its Options (i.e., on a Field-by-Field basis) with respect to an Affini-T Clinical Target by providing written notice to Metagenomi during the Option Period applicable to such Affini-T Clinical Target and such Field by identifying the applicable Affini-T Clinical Target and stating whether an Exclusive License and/or a Non-Exclusive License is being taken with respect to such Affini-T Clinical Target.

  • Each Regulatory Approval milestone shall be payable only once for each Affini-T Clinical Target in each Field regardless of the number of Exclusively Licensed Products or Non-Exclusively Licensed Products associated with such Affini-T Clinical Target that achieve such milestone event.

  • Affini-T shall notify to Metagenomi within [***] after the first achievement of each of the following Regulatory Approval milestone events with respect to each Affini-T Clinical Target once for each Field.

  • In the event a Licensed Product is directed to more than one Affini-T Clinical Target, such Licensed Product shall only trigger payment of applicable Regulatory Approval milestone amounts for a single Affini-T Clinical Target.

  • In the event a Licensed Product is directed to more than one Affini-T Clinical Target, such Licensed Product shall only trigger payment of applicable Development milestone amounts for a single Affini-T Clinical Target.

  • Affini-T may terminate this Agreement (a) in its entirety, or (b) on (i) a Research Plan-by-Research Plan basis, (ii) an Affini-T Clinical Target-by-Affini-T Clinical Target basis, or (iii) a Licensed Product-by-Licensed Product basis (terminations under this subclause (b), a “Partial Termination”), effective at any time by providing not less than sixty (60) days’ prior written notice to Metagenomi.

  • Licensee acknowledges and agrees that the exclusive options granted under Sections 2.2 and 2.3.2 only apply to Research Targets and Pre-Clinical Targets under this Agreement, and that such exclusive options shall not preclude IIPH from granting, for any use and to any Third Party, exclusive options to any Targets that are not a Research Target, Pre-Clinical Target, or Clinical Target under this Agreement.

Related to Clinical Target

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Pivotal Clinical Trial means, with respect to a Licensed Product, (a) a phase 3 Clinical Trial or (b) any other clinical trial that is intended (as of the time the study is initiated) to obtain the results and data to support (without the need to conduct any additional clinical trial) the filing of an application for Regulatory Approval for such product.

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.